A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use-Reference-Cited by-同舟云学术

A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use

Published:2019-10-22 Issue:3 Volume:4 Page:439-447
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Appukkuttan Sreevalsa,Tangirala Krishna,Babajanyan Svetlana,Wen Lonnie,Simmons Stacey,Shore Neal

Funder

Bayer HealthCare Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s41669-019-00185-8.pdf

Reference21 articles.

1. National Cancer Institute. Cancer stat facts: prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html . Accessed 26 Apr 2018.

2. Velcheti V, Kamik S, Bardot S, Prakash O. Pathogenesis of prostate cancer: lessons from basic research. Oschner J. 2008;8:213–8.

3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.

4. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18.

5. Steinburn CN, Fizazi K, Saad F, et al. Prostate specific antigen response in men with nmCRPC (M0 CRPC) treated with enzalutamide. Results from PROSPER. Presented at the European Association of Urology; March 16–20, 2018, Copenhagen.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States;Journal of Managed Care & Specialty Pharmacy;2024-07

2. Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation;Journal of Medical Economics;2024-02-02

3. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States;PharmacoEconomics;2023-11-07

4. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population;Prostate Cancer and Prostatic Diseases;2023-10-02

5. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims;Advances in Therapy;2023-08-02